Acute AT 1 R blockade prevents isoproterenol-induced injury in mdx hearts

Tatyana A. Meyers, Jackie A. Heitzman, Aimee M. Krebsbach, Lauren M. Aufdembrink, Robert Hughes, Alessandro Bartolomucci, DeWayne Townsend

Research output: Contribution to journalArticle

Abstract

Background: Duchenne muscular dystrophy (DMD) is an X-linked disease characterized by skeletal muscle degeneration and a significant cardiomyopathy secondary to cardiomyocyte damage and myocardial loss. The molecular basis of DMD lies in the absence of the protein dystrophin, which plays critical roles in mechanical membrane integrity and protein localization at the sarcolemma. A popular mouse model of DMD is the mdx mouse, which lacks dystrophin and displays mild cardiac and skeletal pathology that can be exacerbated to advance the disease state. In clinical and pre-clinical studies of DMD, angiotensin signaling pathways have emerged as therapeutic targets due to their adverse influence on muscle remodeling and oxidative stress. Here we aim to establish a physiologically relevant cardiac injury model in the mdx mouse, and determine whether acute blockade of the angiotensin II type 1 receptor (AT 1 R) may be utilized for prevention of dystrophic injury. Methods and results: A single IP injection of isoproterenol (Iso, 10 mg/kg) was used to induce cardiac stress and injury in mdx and wild type (C57Bl/10) mice. Mice were euthanized 8 h, 30 h, 1 week, or 1 month following the injection, and hearts were harvested for injury evaluation. At 8 and 30 h post-injury, mdx hearts showed 2.2-fold greater serum cTnI content and 3-fold more extensive injury than wild type hearts. Analysis of hearts 1 week and 1 month after injury revealed significantly higher fibrosis in mdx hearts, with a more robust and longer-lasting immune response compared to wild type hearts. In the 30-hour group, losartan treatment initiated 1 h before Iso injection protected dystrophic hearts from cardiac damage, reducing mdx acute injury area by 2.8-fold, without any significant effect on injury in wild type hearts. However, both wild type and dystrophic hearts showed a 2-fold reduction in the magnitude of the macrophage response to injury 30 h after Iso with losartan. Conclusions: This work demonstrates that acute blockade of AT 1 R has the potential for robust injury prevention in a model of Iso-induced dystrophic heart injury. In addition to selectively limiting dystrophic cardiac damage, blocking AT 1 R may serve to limit the inflammatory nature of the immune response to injury in all hearts. Our findings strongly suggest that earlier adoption of angiotensin receptor blockers in DMD patients could limit myocardial damage and subsequent cardiomyopathy.

Original languageEnglish (US)
Pages (from-to)51-61
Number of pages11
JournalJournal of Molecular and Cellular Cardiology
Volume128
DOIs
StatePublished - Mar 1 2019

Fingerprint

Isoproterenol
Duchenne Muscular Dystrophy
Wounds and Injuries
Heart Injuries
Angiotensin Type 1 Receptor
Inbred mdx Mouse
Dystrophin
Losartan
Cardiomyopathies
Injections
Sarcolemma
Angiotensin Receptor Antagonists
Angiotensins
Cardiac Myocytes
Membrane Proteins
Skeletal Muscle
Oxidative Stress
Fibrosis
Macrophages
Pathology

Keywords

  • Angiotensin
  • Duchenne muscular dystrophy
  • Dystrophic cardiomyopathy
  • Fibrosis
  • Immune infiltration

PubMed: MeSH publication types

  • Journal Article

Cite this

Acute AT 1 R blockade prevents isoproterenol-induced injury in mdx hearts . / Meyers, Tatyana A.; Heitzman, Jackie A.; Krebsbach, Aimee M.; Aufdembrink, Lauren M.; Hughes, Robert; Bartolomucci, Alessandro; Townsend, DeWayne.

In: Journal of Molecular and Cellular Cardiology, Vol. 128, 01.03.2019, p. 51-61.

Research output: Contribution to journalArticle

Meyers, Tatyana A. ; Heitzman, Jackie A. ; Krebsbach, Aimee M. ; Aufdembrink, Lauren M. ; Hughes, Robert ; Bartolomucci, Alessandro ; Townsend, DeWayne. / Acute AT 1 R blockade prevents isoproterenol-induced injury in mdx hearts In: Journal of Molecular and Cellular Cardiology. 2019 ; Vol. 128. pp. 51-61.
@article{54fb32ff02a04df2874f83d5f74735a5,
title = "Acute AT 1 R blockade prevents isoproterenol-induced injury in mdx hearts",
abstract = "Background: Duchenne muscular dystrophy (DMD) is an X-linked disease characterized by skeletal muscle degeneration and a significant cardiomyopathy secondary to cardiomyocyte damage and myocardial loss. The molecular basis of DMD lies in the absence of the protein dystrophin, which plays critical roles in mechanical membrane integrity and protein localization at the sarcolemma. A popular mouse model of DMD is the mdx mouse, which lacks dystrophin and displays mild cardiac and skeletal pathology that can be exacerbated to advance the disease state. In clinical and pre-clinical studies of DMD, angiotensin signaling pathways have emerged as therapeutic targets due to their adverse influence on muscle remodeling and oxidative stress. Here we aim to establish a physiologically relevant cardiac injury model in the mdx mouse, and determine whether acute blockade of the angiotensin II type 1 receptor (AT 1 R) may be utilized for prevention of dystrophic injury. Methods and results: A single IP injection of isoproterenol (Iso, 10 mg/kg) was used to induce cardiac stress and injury in mdx and wild type (C57Bl/10) mice. Mice were euthanized 8 h, 30 h, 1 week, or 1 month following the injection, and hearts were harvested for injury evaluation. At 8 and 30 h post-injury, mdx hearts showed 2.2-fold greater serum cTnI content and 3-fold more extensive injury than wild type hearts. Analysis of hearts 1 week and 1 month after injury revealed significantly higher fibrosis in mdx hearts, with a more robust and longer-lasting immune response compared to wild type hearts. In the 30-hour group, losartan treatment initiated 1 h before Iso injection protected dystrophic hearts from cardiac damage, reducing mdx acute injury area by 2.8-fold, without any significant effect on injury in wild type hearts. However, both wild type and dystrophic hearts showed a 2-fold reduction in the magnitude of the macrophage response to injury 30 h after Iso with losartan. Conclusions: This work demonstrates that acute blockade of AT 1 R has the potential for robust injury prevention in a model of Iso-induced dystrophic heart injury. In addition to selectively limiting dystrophic cardiac damage, blocking AT 1 R may serve to limit the inflammatory nature of the immune response to injury in all hearts. Our findings strongly suggest that earlier adoption of angiotensin receptor blockers in DMD patients could limit myocardial damage and subsequent cardiomyopathy.",
keywords = "Angiotensin, Duchenne muscular dystrophy, Dystrophic cardiomyopathy, Fibrosis, Immune infiltration",
author = "Meyers, {Tatyana A.} and Heitzman, {Jackie A.} and Krebsbach, {Aimee M.} and Aufdembrink, {Lauren M.} and Robert Hughes and Alessandro Bartolomucci and DeWayne Townsend",
year = "2019",
month = "3",
day = "1",
doi = "10.1016/j.yjmcc.2019.01.013",
language = "English (US)",
volume = "128",
pages = "51--61",
journal = "Journal of Molecular and Cellular Cardiology",
issn = "0022-2828",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Acute AT 1 R blockade prevents isoproterenol-induced injury in mdx hearts

AU - Meyers, Tatyana A.

AU - Heitzman, Jackie A.

AU - Krebsbach, Aimee M.

AU - Aufdembrink, Lauren M.

AU - Hughes, Robert

AU - Bartolomucci, Alessandro

AU - Townsend, DeWayne

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Background: Duchenne muscular dystrophy (DMD) is an X-linked disease characterized by skeletal muscle degeneration and a significant cardiomyopathy secondary to cardiomyocyte damage and myocardial loss. The molecular basis of DMD lies in the absence of the protein dystrophin, which plays critical roles in mechanical membrane integrity and protein localization at the sarcolemma. A popular mouse model of DMD is the mdx mouse, which lacks dystrophin and displays mild cardiac and skeletal pathology that can be exacerbated to advance the disease state. In clinical and pre-clinical studies of DMD, angiotensin signaling pathways have emerged as therapeutic targets due to their adverse influence on muscle remodeling and oxidative stress. Here we aim to establish a physiologically relevant cardiac injury model in the mdx mouse, and determine whether acute blockade of the angiotensin II type 1 receptor (AT 1 R) may be utilized for prevention of dystrophic injury. Methods and results: A single IP injection of isoproterenol (Iso, 10 mg/kg) was used to induce cardiac stress and injury in mdx and wild type (C57Bl/10) mice. Mice were euthanized 8 h, 30 h, 1 week, or 1 month following the injection, and hearts were harvested for injury evaluation. At 8 and 30 h post-injury, mdx hearts showed 2.2-fold greater serum cTnI content and 3-fold more extensive injury than wild type hearts. Analysis of hearts 1 week and 1 month after injury revealed significantly higher fibrosis in mdx hearts, with a more robust and longer-lasting immune response compared to wild type hearts. In the 30-hour group, losartan treatment initiated 1 h before Iso injection protected dystrophic hearts from cardiac damage, reducing mdx acute injury area by 2.8-fold, without any significant effect on injury in wild type hearts. However, both wild type and dystrophic hearts showed a 2-fold reduction in the magnitude of the macrophage response to injury 30 h after Iso with losartan. Conclusions: This work demonstrates that acute blockade of AT 1 R has the potential for robust injury prevention in a model of Iso-induced dystrophic heart injury. In addition to selectively limiting dystrophic cardiac damage, blocking AT 1 R may serve to limit the inflammatory nature of the immune response to injury in all hearts. Our findings strongly suggest that earlier adoption of angiotensin receptor blockers in DMD patients could limit myocardial damage and subsequent cardiomyopathy.

AB - Background: Duchenne muscular dystrophy (DMD) is an X-linked disease characterized by skeletal muscle degeneration and a significant cardiomyopathy secondary to cardiomyocyte damage and myocardial loss. The molecular basis of DMD lies in the absence of the protein dystrophin, which plays critical roles in mechanical membrane integrity and protein localization at the sarcolemma. A popular mouse model of DMD is the mdx mouse, which lacks dystrophin and displays mild cardiac and skeletal pathology that can be exacerbated to advance the disease state. In clinical and pre-clinical studies of DMD, angiotensin signaling pathways have emerged as therapeutic targets due to their adverse influence on muscle remodeling and oxidative stress. Here we aim to establish a physiologically relevant cardiac injury model in the mdx mouse, and determine whether acute blockade of the angiotensin II type 1 receptor (AT 1 R) may be utilized for prevention of dystrophic injury. Methods and results: A single IP injection of isoproterenol (Iso, 10 mg/kg) was used to induce cardiac stress and injury in mdx and wild type (C57Bl/10) mice. Mice were euthanized 8 h, 30 h, 1 week, or 1 month following the injection, and hearts were harvested for injury evaluation. At 8 and 30 h post-injury, mdx hearts showed 2.2-fold greater serum cTnI content and 3-fold more extensive injury than wild type hearts. Analysis of hearts 1 week and 1 month after injury revealed significantly higher fibrosis in mdx hearts, with a more robust and longer-lasting immune response compared to wild type hearts. In the 30-hour group, losartan treatment initiated 1 h before Iso injection protected dystrophic hearts from cardiac damage, reducing mdx acute injury area by 2.8-fold, without any significant effect on injury in wild type hearts. However, both wild type and dystrophic hearts showed a 2-fold reduction in the magnitude of the macrophage response to injury 30 h after Iso with losartan. Conclusions: This work demonstrates that acute blockade of AT 1 R has the potential for robust injury prevention in a model of Iso-induced dystrophic heart injury. In addition to selectively limiting dystrophic cardiac damage, blocking AT 1 R may serve to limit the inflammatory nature of the immune response to injury in all hearts. Our findings strongly suggest that earlier adoption of angiotensin receptor blockers in DMD patients could limit myocardial damage and subsequent cardiomyopathy.

KW - Angiotensin

KW - Duchenne muscular dystrophy

KW - Dystrophic cardiomyopathy

KW - Fibrosis

KW - Immune infiltration

UR - http://www.scopus.com/inward/record.url?scp=85060330983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060330983&partnerID=8YFLogxK

U2 - 10.1016/j.yjmcc.2019.01.013

DO - 10.1016/j.yjmcc.2019.01.013

M3 - Article

VL - 128

SP - 51

EP - 61

JO - Journal of Molecular and Cellular Cardiology

JF - Journal of Molecular and Cellular Cardiology

SN - 0022-2828

ER -